Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Trading Update

31 May 2012 07:00

RNS Number : 4649E
Biome Technologies PLC
31 May 2012
 



Biome Technologies plc ("Biome", "the Company" or "the Group")

Trading Update

 

In the trading statement released by Biome on 25 April, it was stated that revenues were slower to achieve than expected in the first quarter, particularly in the Bioplastics Division. Unfortunately, sales within this division have been markedly below our expectation during April and May. The Board now believes that this will have a significant adverse impact on the Group results for the full year; this will be particularly felt in the first half. The RF Division is trading in line with the Board's expectations and its order pipeline remains strong.

 

Customers of the Group's Bioplastics Division are reporting subdued demand for their own bioplastic end products, particularly in the markets of southern Europe. During 2011, the Italian market for bioplastics became one of the largest in Europe following the implementation of regulations (first introduced in early 2011 and reaffirmed in early 2012) mandating the use of biodegradable products for shopping bags. However, in the early part of May this year Biome became aware that the financial penalty for non-compliance with these regulations would now be deferred until the end of 2013. This has resulted in the recent and significant change in the adoption rate in the Italian market and a broader disruption to the supply and demand balance of bioplastics in Europe. In the current, year the Board expects its joint venture company, Biotec, to be the most adversely affected part of the Group.

 

The impact of these changes to the dynamics of the bioplastics' market will result in it taking longer than previously anticipated for the Group to reach profitability. The Group's cash balance as at the end of April was £1.4m. However, this would have reduced significantly as the year progressed unless action is taken to reduce costs. As a result, the Board is taking steps to reduce cash costs by approximately £600k per year. This will better preserve Biome's ability to reach profitability and protect its business model.

 

Whilst the above developments, which affect the fast development of Biome's bio-plastics market, are disappointing, the Board believes firmly that they constitute a pause in a fast-developing market rather than an indication of anything more fundamental.

 

Biome continues to progress successfully with new products and technologies to improve its future prospects and develop new markets. The RF Division is performing well and remains a cash generator for the group as a whole. The Durapipe project remains on track and is successfully passing agreed milestones with our partner. The new technology for heat and cold resistant bio-plastic materials continues to gain positive reaction from product tests with prospective customers. The Board expects these new developments to make contributions to turnover in 2013.

 

-Ends-

 

 

For further information please contact:

 

Biome Technologies plc

Paul Mines, Chief Executive Officer

Declan Brown, Group Finance Director

www.biometechnologiesplc.com Tel: +44 (0) 2380 867 100

 

Daniel Stewart & Company plc

David Hart

www.danielstewart.co.uk Tel: +44 (0) 20 7776 6550

 

First Columbus

Chris Crawford/Kelly Gardiner

www.first-columbus.com Tel: +44 (0) 20 3002 2070

 

FTI Consulting

Oliver Winters/Latika Shah Tel: +44 (0) 20 7831 3113

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBKKDPABKDBPN
Date   Source Headline
27th Apr 20071:34 pmRNSResult of AGM
27th Apr 20071:32 pmRNSDirectorate Change
26th Apr 20071:42 pmRNSAnnual Information Update
13th Apr 200712:29 pmRNSDirector's Dealing
30th Mar 20071:32 pmRNSAnnual Report and Accounts
23rd Mar 20075:09 pmRNSNotifiable Interest
21st Mar 20077:03 amRNSPreliminary Results
14th Mar 20075:59 pmRNSHolding(s) in Company
26th Feb 20077:01 amRNSBoard Appointment
23rd Feb 20073:18 pmRNSHolding(s) in Company
30th Jan 20079:00 amRNSNotice of Results
18th Dec 20064:58 pmRNSTotal Voting Rights
8th Dec 200612:31 pmRNSNotifiable Interest
28th Nov 20063:32 pmRNSNotifiable Interest
17th Nov 20063:33 pmRNSNotifiable Interest
16th Nov 20069:02 amRNSNotifiable Interest
14th Nov 20064:37 pmRNSDirectorate Change
14th Nov 20064:09 pmRNSDirector/PDMR Shareholding
14th Nov 20064:03 pmRNSNotifiable Interest
14th Nov 20069:55 amRNSNotifiable Interest
10th Nov 200610:29 amRNSHolding(s) in Company
9th Nov 200611:45 amRNSNotifiable Interest
8th Nov 20063:08 pmRNSNotifiable Interest
7th Nov 20068:01 amRNSIssue of Equity
6th Nov 200612:12 pmRNSResult of EGM
3rd Nov 20064:41 pmRNSNotifiable Interest
3rd Nov 20061:17 pmRNSOpen Offer Result - Amendment
2nd Nov 20066:03 pmRNSOpen Offer Result
31st Oct 200611:54 amRNSNotifiable Interest
17th Oct 20065:54 pmRNSNotifiable Interest
17th Oct 200610:44 amRNSNotifiable Interest
16th Oct 20063:17 pmRNSNotifiable Interest
12th Oct 200612:35 pmRNSDoc re. Posting of Prospectus
11th Oct 20061:09 pmRNSNotifiable Interest
9th Oct 200611:13 amRNSProposed Placing & Open Offer
5th Oct 200610:25 amRNSFinancing Update
3rd Oct 200612:56 pmRNSStatement re. Press Comment
2nd Oct 20064:41 pmRNSSecond Price Monitoring Extn
2nd Oct 20064:35 pmRNSPrice Monitoring Extension
8th Sep 20067:01 amRNSTrading Statement
17th Aug 20067:44 amRNSTrading Statement
16th Aug 20065:52 pmRNSAdditional Listing - AMEND
14th Aug 200611:55 amRNSAdditional Listing
10th Aug 200612:25 pmRNSRe Contract
14th Jul 20067:56 amRNSInterim Results - Replacement
14th Jul 20067:00 amRNSInterim Results
2nd Jun 200611:26 amRNSNew Ord Share Placing-Amendmt
2nd Jun 20068:45 amRNSNew Ordinary Share Placing
25th May 20067:02 amRNSWrap 100 FDA approval
16th May 200610:43 amRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.